The 스마트 링 market was supposed to be a quiet niche. Then Samsung entered with the Galaxy Ring, and Oura -- the Finnish company that spent a decade building this category -- decided to fight back with lawyers.
What followed is the most significant patent dispute in 웨어러블 health tech since Fitbit vs. Jawbone. The 스마트 링 market is projected to hit $5.4 billion by 2028, and these legal outcomes will determine who gets to compete in it.
14
Active patent claims
Filed across US, EU, and South Korea
$2.1B
Market at stake
2026 projected smart ring revenue
3
Major companies involved
Oura, Samsung, Ultrahuman
2028
Earliest resolution
Full litigation timeline estimate
How Oura Built Its Legal Moat
Oura did not just popularize the 스마트 링 -- it essentially invented the modern category in 2015. Over eight years, the company built a portfolio of 70+ granted patents and 120+ pending applications covering:
- PPG sensor placement geometry in ring form factors
- Signal processing algorithms for finger-based arterial blood flow
- Temperature sensing methods via embedded infrared thermistors
- Sleep staging algorithms fusing HRV, temperature, and motion from a ring
- Ring-specific noise filtering for finger-worn motion artifacts
Every meaningful approach to building a health-sensing ring touches at least a few of these claims.
Why Finger Placement Matters Legally
Oura's patents cover the specific engineering solutions required to exploit finger-based vascular anatomy -- not just "a ring that measures health." This specificity makes them harder to design around than broader 웨어러블 patents.
Samsung Enters -- Oura Strikes
Samsung launched the Galaxy Ring in July 2024 at $399, directly competing with Oura. Within months, Oura filed an ITC complaint (which could ban Galaxy Ring imports entirely) plus a federal lawsuit. Samsung countersued. The battle escalated from there.
| Date | Action | By Whom |
|---|---|---|
| Oct 2024 | ITC complaint + federal lawsuit | Oura vs. Samsung |
| Dec 2024 | Countersuit (3 patents) | Samsung vs. Oura |
| May 2025 | Ultrahuman added to ITC complaint | Oura vs. Ultrahuman |
| Aug 2025 | IPR petitions on 3 Oura patents | Samsung at USPTO |
| Jan 2026 | ITC preliminary ruling -- partial infringement | ITC |
| Feb 2026 | Countersuit filed in South Korea | Samsung vs. Oura |
What Is Actually Being Fought Over
The core disputes break into three categories.
PPG Sensor Architecture: Oura's patents describe specific LED and photodetector arrangements on the inner ring surface. Samsung's Galaxy Ring uses a functionally similar layout. Samsung argues the physics of finger anatomy dictates placement, making Oura's patents invalid.
Continuous Temperature Monitoring: Oura patented the method of using embedded thermistors to detect temperature deviation from a personal baseline for illness prediction. Both Samsung and Ultrahuman implement similar features.
Multi-Signal 수면 단계 분류: Oura's patents describe ML models that fuse HRV, accelerometer, and temperature signals from a ring. Samsung's IPR petitions target these specifically, arguing they are obvious combinations of pre-existing techniques.
Samsung's Best Weapon: IPR Petitions
Inter partes review at the USPTO allows Samsung to challenge Oura's patent validity independently of the ITC case. PTAB invalidates claims in 60--70% of instituted IPR proceedings. If key patents fall, the entire ITC case weakens.
Ultrahuman: Caught in the Crossfire
Oura added Ultrahuman to the ITC complaint in May 2025. The strategic signal: Oura will pursue any competitor using overlapping ring technology.
The problem? Samsung has 150,000+ patents and unlimited legal budget. Ultrahuman is a $35M Series B startup. A prolonged patent war could drain resources meant for product development.
wearable-health-tech
Unify all your wearable data and get personalized AI health insights in one place.
| Factor | Oura | Samsung | Ultrahuman |
|---|---|---|---|
| Patent portfolio | 70+ granted | 150,000+ | ~15 granted |
| Annual revenue | $300-400M | $211B | $40-60M |
| US ring market share | ~65% | ~20% | ~8% |
| Legal budget | Moderate | Unlimited | Limited (VC-funded) |
Ultrahuman's Geographic Shield
Ultrahuman's primary market is India, where Oura has limited patent coverage. Even a US import ban would not stop Indian and Southeast Asian sales. But losing the US market would severely damage growth and future fundraising.
What This Means for You
Should You Wait to Buy?
No. Legal proceedings will not affect products currently on sale. Existing Galaxy Rings and Ring Airs will continue to function and receive updates. Only future product launches could be affected -- and that is 12--24 months away at minimum.
If Oura wins broadly: Less competition, higher prices, slower innovation. Competitors pay royalties or exit the US market temporarily.
If Samsung wins (patents invalidated): Market opens wide. Google, Apple, Xiaomi enter with reduced risk. Prices drop. Innovation accelerates.
If they settle (most likely): Cross-licensing agreement. Samsung pays Oura per-unit royalties. Prices increase $10--15 per ring. Ultrahuman may be excluded and face continued pressure.
The ITC found partial infringement on two of five patents in January 2026. A full hearing is expected Q3 2026. Samsung's PTAB decisions arrive Q2 2026. The most realistic resolution: a cross-licensing deal within the next 12 months, with per-unit royalties and continued market access for all players.
Frequently Asked Questions
Not imminently. Even with an ITC exclusion order, Samsung can post a bond and continue importing during the 60-day Presidential review. Realistically, Samsung would negotiate a license or redesign before any ban takes effect. Current devices are unaffected.
Moderately, yes. A licensing settlement would likely add $5-25 per ring in royalties, with $10-15 passed to consumers. On a $349-399 device, that is a modest increase.
Very similar. Masimo sued Apple at the ITC over SpO2 patents, won an exclusion order, and Apple had to modify its algorithm. Oura is following the same playbook. The key difference: Samsung and Apple both have resources to rapidly redesign, but Ultrahuman may not.
Yes, but Oura's portfolio creates a significant barrier. Apple has been granted ring-related patents (suggesting development). Google has Fitbit's wearable IP. The resolution of this case will heavily influence if and when they enter.
If Oura's patents hold, it validates narrow form-factor-specific patent portfolios and encourages aggressive patenting. If invalidated, it signals wearable health tech is too incremental for strong protection -- accelerating commoditization and competition.
